



May 19<sup>th</sup>, 2014

VRL/SEC/BSE

Dept. of Corporate Services  
The Stock Exchange, Mumbai  
25<sup>th</sup> Floor, Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai

Sub. : Venus Remedies bags Market Authorization of Meropenem Injection from TGA, Australia

Dear Sir/Madam,

This is to inform you that Venus Remedies Limited has received marketing authorization approval from Therapeutic Goods Administration (TGA) of Australia for meropenem. The company has a tie up with Lupin to launch this drug in Australia. With this MA grant, Venus has total 35 market authorizations from various continents across the globe and holds a significant market share.

Meropenem is a broad spectrum anti-bacterial agent of carbapenem family, a product used as last resort in ICUs, indicated as empirical therapy prior to the identification of causative organisms, or for diseases caused by single or multiple susceptible bacteria in both adults and children with a broad range of serious infections.



MA grants from TGA has opened doors to enter into a market of US \$15 million for penems in Australia. Company is planning to launch Meropenem in Australia by 3<sup>rd</sup> Quarter 2014 and eyeing to capture sizeable market share in Australia's \$-15 million meropenem market in the first year of launch. Meropenem has an approximately \$1.3 billion market across the globe.

Presently, Venus is already selling meropenem in highly lucrative markets like Europe, New Zealand, Saudi Arabia and is in the process of extending its footprints and sales operations in the most of other regulated markets like Canada and Switzerland also. Venus has already received marketing approval for Meropenem from more than 30 countries and is generating good revenue from the export of meropenem from these EU markets.

Venus was the first company from India to have dedicated penems manufacturing facility which is EU GMP certified. Meropenem market authorisation grants from TGA once again proved company's capabilities and its expertise in developing world class products with regulatory might.

## VENUS REMEDIES LIMITED

Corporate Office :  
51-52, Industrial Area, Phase- 1,  
Panchkula (Hry.) 134113, India  
Regd. Office :  
SCO 857, Cabin No. 10, 2nd Floor, NAC,  
Manimajra, Chandigarh (U.T.) 160101, India  
Website : [www.venusremedies.com](http://www.venusremedies.com)  
[www.venusmedicineresearchcentre.com](http://www.venusmedicineresearchcentre.com)



Unit-I :  
51-52, Industrial Area, Phase-1, Panchkula (Hry.) 134113, India  
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566  
Unit-II :  
Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),  
Bhatoli Katm, Baddi (H.P.) 173205, India  
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271277  
Unit-V :  
VENUS PHARMA GmbH  
AM Bahnhof 1-3, D-59368, Werne, Germany



With these milestones, Venus shall be able to capture a significant share of the Meropenem market globally since Venus has competitive edge against other players. The company is successfully doing so through various tie-ups in these countries.

Yours faithfully,  
for VENUS REMEDIES LIMITED.

*Ramajit*  
Ramajit Kaur  
Deputy Manager  
Corporate Communication



## VENUS REMEDIES LIMITED

**Corporate Office :**  
51-52, Industrial Area, Phase-I,  
Panchkula (Hry.) 134113, India  
**Regd. Office :**  
SCO 857, Cabin No. 10, 2nd Floor, NAC,  
Manmarg, Chandigarh (U.T.) 160101, India  
**Website :** [www.venusremedies.com](http://www.venusremedies.com)  
[www.venusmedicineresearchcentre.com](http://www.venusmedicineresearchcentre.com)



**Unit-I :**  
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India  
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566  
**Unit-II :**  
Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),  
Bhatoli Kalan, Baddi (H.P.) 173205, India  
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272  
**Unit-V :**  
VENUS PHARMA GmbH  
AM Bahnhof 1-3, D-59368, Werne, Germany